A Diamine-PEGylated Oleanolic Acid Derivative Induced Efficient Apoptosis through a Death Receptor and Mitochondrial Apoptotic Pathway in HepG2 Human Hepatoma Cells
Metadata
Show full item recordAuthor
Jannus, Fatin; Medina-O'Donnell, Marta; Rivas Sánchez, Francisco De Asís; Díaz Ruiz, Luis; Rufino Palomares, Eva; Lupiáñez Cara, José Antonio; Parra Sánchez, Andrés; Reyes Zurita, Fernando JesúsEditorial
MDPI
Materia
Triterpenes Oleanolic acid (PEG)ylated oleanolic acid Extrinsic apoptotic pathway Anti-tumor mechanisms Hepatocellular carcinoma
Date
2020Referencia bibliográfica
Jannus F, Medina-O’Donnell M, Rivas F, Díaz-Ruiz L, Rufino-Palomares EE, Lupiáñez JA, Parra A, Reyes-Zurita FJ. A Diamine-PEGylated Oleanolic Acid Derivative Induced Efficient Apoptosis through a Death Receptor and Mitochondrial Apoptotic Pathway in HepG2 Human Hepatoma Cells. Biomolecules. 2020; 10(10):1375. [https://doi.org/10.3390/biom10101375]
Sponsorship
Junta de Andalucia B1-BIO-281-UGR18 B1-FQM-217-UGR18Abstract
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Our recent
studies have shown that the diamine-(PEG)ylated oleanolic acid (OADP) has strong anti-tumor
effects in HCCs. In this study, we evaluated the anti-tumor mechanisms of OADP in the HepG2
HCC cell line. The cytotoxicity results showed that HepG2 cell viability was markedly reduced,
with a very low 50% of cell growth inhibitory concentration (IC50, 0.14 µg/mL). We then investigated
the anti-tumor mechanisms of OADP in HepG2 cells. The flow-cytometry analysis was used to
evaluate cell apoptosis, indicating that 74–95% of cells were apoptotic. OADP caused cell cycle arrest
in the G0/G1 phase and the loss of the mitochondrial membrane potential (MMP). Western blot
analysis was performed to assess the expression levels of key proteins associated with the underlying
molecular mechanism. The results showed the clear upregulation of caspase-8, caspase-9, caspase-3,
Bak, p21, and p53, accompanied by the downregulation of Bcl-2. Similar results were obtained by the
cotreatment with OADP and the c-Jun N-terminal kinase (JNK) inhibitor SP600125. Agents such as
OADP, which are capable of activating extrinsic and intrinsic apoptotic pathways, may represent
potential HCC cancer therapies.